Navigation Links
Fetal Exposure to Common Epilepsy Drugs May Harm Kids' IQ: FDA
Date:6/30/2011

THURSDAY, June 30 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday advised doctors to warn women of childbearing age that fetal exposure to certain drugs used to control seizures or migraines appears to diminish intellectual abilities in offspring.

The drugs include so-called "valproate products" -- medications such as valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, Depakote ER), valproic acid (Depakene, Stavzor), and their equivalent generic formulations, the FDA said in a statement.

Children born to women who take these medications during their pregnancy "have an increased risk of lower cognitive test scores than children exposed to other anti-seizure medications during pregnancy," the FDA said.

The agency said it based its conclusions on epidemiological studies that showed that fetal exposures to the drugs tended to correlate with lower scores on IQ and other cognitive tests.

Valproate drugs are FDA-approved for use against epilepsy, migraine and bipolar disorder, although the agency notes that they are also used "off-label" for other conditions, mainly other psychiatric disorders.

The drugs have also long been linked to an increased risk of birth defects known as neural tube defects, the agency noted.

The FDA advises that doctors counsel women of childbearing age of the risks to offspring associated with valproate products, and "weigh the benefits and risks of valproate when prescribing this drug to women of childbearing age, particularly when treating a condition not usually associated with permanent injury or death. Alternative medications that have a lower risk of adverse birth outcomes should be considered."

In late 2010, a Swedish study of over 1,200 teenage children born to women with epilepsy found that those born to women who took two or more epilepsy drugs while pregnant fared worse in school than peers with no prenatal exposure to those medications.

The findings, published in Epilepsia, echoed earlier research that linked prenatal exposure to epilepsy drugs, particularly valproic acid medications (such as Depakene and Depakote), to negative effects on a child's ability to process information, solve problems and make decisions.

"Our results suggest that exposure to several anti-epileptic drugs in utero may have a negative effect on a child's neurodevelopment," study author Dr. Lisa Forsberg of Karolinska University Hospital told HealthDay at the time.

Forsberg recommended that women with epilepsy plan their pregnancies. "That way, they and their doctors can come up with individual treatment plans that make the pregnancy safe for both mother and child," she said.

More information

To learn more about women and epilepsy, visit the Epilepsy Foundation.

-- HealthDay Staff

SOURCES: Lisa Forsberg, M.D., Karolinska University Hospital, Stockholm, Sweden; U.S. Food and Drug Administration, news release, June 30, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Ultrasensitive detector pinpoints big problem in tiny fetal heart
2. Fetal alcohol spectrum disorder linked to high prevalence of epilepsy, Queens study
3. Study finds changes in fetal epigenetics throughout pregnancy
4. Hurricanes Linked to Raised Fetal Distress Risk
5. AIUM announces ultrasound practice accreditation in fetal echocardiography
6. Figuring out fetal alcohol syndrome in fruit flies
7. Fetal Surgery Could Boost Outcomes in Severe Spina Bifida
8. Study finds even with fetal lung maturity, babies delivered prior to 39 weeks are at risk
9. Study finds that electronic fetal heart rate monitoring greatly reduces infant mortality
10. Society for Maternal-Fetal Medicine commends FDA on makena announcement
11. The TET1 enzyme steers us through fetal development and fights cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fetal Exposure to Common Epilepsy Drugs May Harm Kids' IQ: FDA
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: